BioCentury | Dec 21, 2015
Emerging Company Profile

New purpose in flu

Atriva Therapeutics GmbH is repurposing MEK inhibitors to stop influenza viruses from hijacking host cellular pathways necessary for viral replication. The strategy may provide better efficacy than existing flu therapies by avoiding viral resistance. Roche's...
Items per page:
1 - 1 of 1